ClinicalTrials.gg
CompletedNCT01474330Updated Nov 12, 2019

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

A Phase 1 interventional study of Pomalidomide and Placebo in Healthy, sponsored by Celgene. Completed at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-11-12.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Aug 2011, registered Nov 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

To evaluate the safety, tolerability, and pharmacokinetics of pomalidomide administered orally once a day for 5 days, at daily doses of 0.5 mg, 1 mg, or 2 mg.

02

Conditions studied

  • Healthy

Keywords

  • Pomalidomide
  • safety
  • tolerability
  • pharmacokinetics
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy male subjects of any ethnic origin between ages of 18 and 55 with a between 19 and 30

Exclusion criteria

Exclusion Criteria:

  1. Any condition, including the presence of laboratory abnormalities, or psychiatric illness, that would prevent the subject from signing the Document (ICD), places the subject at unacceptable risk if he were to participate in the study, or confounds the ability to interpret data from the study.
  2. Presence of any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, or plans to have elective or medical procedures during the conduct of the trial.
  3. Exposure to an drug (new chemical entity) within 30 days prior to the first dose administration or 5 half-lives of that investigational drug, if known (whichever is longer).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    0.5-mg Pomalidomide or placebo (Cohort A)

    A single 0.5-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions

    Drug: Pomalidomide · Drug: Placebo

  • Experimental
    1-mg Pomalidomide or placebo (Cohort B)

    This arm may be initiated pending a safety review of Cohort A. A single 1-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.

    Drug: Pomalidomide · Drug: Placebo

  • Experimental
    2-mg Pomalidomide or placebo (Cohort C)

    This arm may be initiated pending a safety review of Cohort B. A single 2-mg pomalidomide capsule or matching placebo administered once daily for 5 days under fasted conditions.

    Drug: Pomalidomide · Drug: Placebo

Interventions

  • 0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions

    Also known as: CC-4047

  • DrugPlacebo

    Placebo capsule

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Number of participants with adverse events

    Time frame: 28 days after last dose

  2. area under the plasma concentration-time curve

    area under the plasma concentration-time curve

    Time frame: 72 hours after last dose

  3. time to maximum observed plasma concentration

    time to maximum observed plasma concentration

    Time frame: 72 hours after last dose

Secondary outcomes

  1. maximum observed plasma concentration

    maximum observed plasma concentration

    Time frame: 72 hours after last dose

  2. terminal elimination half-life

    terminal elimination half-life

    Time frame: 72 hours after last dose

  3. apparent total plasma clearance

    apparent total plasma clearance

    Time frame: 72 hours after last dose

  4. apparent total volume of distribution, and accumulation ratio

    apparent total volume of distribution, and accumulation ratio

    Time frame: 72 hours after last dose

07

Study locations

1 site
  • PPD Phase I Clinic
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2011 to primary completion in Oct 2011, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2011
First posted
Nov 18, 2011
StartActual
Aug 1, 2011
Primary completionActual
Oct 1, 2011
CompletionActual
Oct 1, 2011
Last update
Nov 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01474330
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Nov 18, 2011
Start date
Aug 1, 2011
Primary completion
Oct 1, 2011
Completion
Oct 1, 2011
Last update
Nov 12, 2019

Study contacts

Maria Palmisano
study director · Celgene

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pomalidomide

Start the discussion